Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774578 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01774578 is a Phase 2 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 135 participants.
The verdict
NCT01774578, a Phase 2 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Gemcitabine
- BIOLOGICAL HyperAcute®-Lung Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774578
The ClinicalTrials.gov registry entry for NCT01774578 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01774578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774578 about?
NCT01774578 is a clinical study titled "Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer". The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
What is the current status of trial NCT01774578?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2013-02. Estimated completion is 2016-06-18.
What interventions are being tested in trial NCT01774578?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), HyperAcute®-Lung Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01774578?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.